Q3 2020-21 Initiation																
d	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173667	20/EE/0101	281712	Randomised Evaluation of COVID-19 Therapy (RECOVERY)	Yes	08/04/2020	12	8	20	19/03/2020	19/03/2020	17/03/2020	13/03/2020	31/03/2020	Please Select...	31/03/2020	Please Select...

173668	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC inhibitor medication called ION-827359 in Healthy Volunteers and People With Cystic Fibrosis	No		21			31/10/2019	06/01/2020	11/12/2019	07/01/2020	27/01/2020	Please Select...	27/02/2020	Neither
173669	18/LO/0660	237150	Randomized, Embedded, Multifactorial, Adaptive Platform trial for Community-Acquired Pneumonia	No		14			27/03/2020	31/03/2020	23/07/2018	06/04/2020	14/04/2020	Please Select...	14/04/2020	Neither

173670	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	No		0			14/04/2020	17/04/2020	03/04/2020	17/04/2020	17/04/2020	Please Select...	17/04/2020	Neither
173671	20/NW/0195	1003047	A Phase 3b randomised, placebo-controlled study of the efficacy and safety of a triple combination therapy of elexacaftor (VX-445), tezacaftor and ivacaftor in people with cystic fibrosis aged 6 to 11 with	No		104			28/02/2020	14/05/2020	14/05/2020	18/05/2020	26/08/2020	Please Select...	27/08/2020	Neither

173795	19/LO/1427	269494	Oscillatory Positive Expiratory Pressure (OPEP) devices to improve outcome in patients with Chronic Obstructive Pulmonary Disease (COPD)	Yes	03/03/2020	29	13	42	21/01/2020	21/01/2020	08/01/2020	17/02/2020	19/02/2020	Please Select...	19/02/2020	Please Select...
173796	19/LO/1660	271589	Oral Nitrate supplementation and Blood pressure in COPD ? a randomised clinical trial. (The ON-BC study)	No		27			21/01/2020	21/01/2020	10/01/2020	17/02/2020	17/02/2020	Please Select...	17/02/2020	Neither

173797	20/LO/0362	277149	Open-Label, Baseline-Controlled, Two-Period, Exploratory Study of Safety, Tolerability and Pharmacodynamics of Oral MYK-491 in Stable Ambulatory Patients with Primary Dilated Cardiomyopathy Associated with MYH7 Mutation	Yes	16/03/2021	279	132	411	28/10/2019	30/01/2020	02/03/2020	04/12/2020	04/11/2020	Please Select...	09/12/2020	Sponsor
173798	19/NS/0060	230919	CYtosorb modulation of surgiCal infLammatiON during LVAD insErtion (CYCLONE-LVAD) study	Yes	14/10/2020	20	226	246	11/02/2020	11/02/2020	13/06/2019	13/02/2020	02/03/2020	Please Select...	02/03/2020	Neither

173799	19/LO/1606	266521	Decision support system to evaluate VENTilation in ARDS (DeVENT)	Yes	19/03/2020	14	17	31	17/02/2020	17/02/2020	13/06/2019	27/02/2020	02/03/2020	Please Select...	02/03/2020	Please Select...
173800	20/SC/0071	263083	High density substrate evaluation and guided ablation therapy for atrial fibrillation: Heat-AF	No		230			29/01/2020	01/04/2020	03/04/2020	17/11/2020	17/11/2020	Please Select...	17/11/2020	NHS Provider

173801	26/NW/0004	274499	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older	Yes	26/06/2020	24	39	63	19/02/2020	24/04/2020	24/04/2020	24/04/2020	18/05/2020	Please Select...	18/05/2020	Please Select...

173802	20/LO/0749	1003158	A randomized, patients- and investigator blinded, placebo - controlled parallel group study to assess the mode-of-action of QBW251 in patients with Chronic Obstructive Lung disease (COPD).	No		217			31/12/2019	11/05/2020	26/06/2020	10/12/2020	14/12/2020	Please Select...	15/12/2020	Neither
173803	20/SC/0315	285603	EARSATS-19: In-ear measurement of blood oxygen saturation in COVID-19 follow up	No		48			20/08/2020	19/08/2020	19/08/2020	19/08/2020	06/10/2020	Please Select...	20/10/2020	Neither

173804	20/NW/0089	275309	Grass Pollen Sublingual Tablet Immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Moderate to Severe Seasonal Allergic Rhinitis	Yes	04/01/2021	24	77	101	04/03/2019	25/09/2020	20/03/2020	19/10/2020	19/10/2020	Please Select...	19/10/2020	Sponsor
173805	20/NI/0137	285414	Fissure Closure with the AeriSeal? System for Converting Collateral Ventilation Status in Patients with Severe Emphysema; a Multicenter, Prospective Trial	No		141			29/09/2020	30/09/2020	27/01/2021	08/02/2021	18/02/2021	Please Select...	18/02/2021	NHS Provider

173806	19/EM/0315	258745	Peri-Vascular adipose tissue inflammation Elevated using coronary CT angiography (P-VECT Study)	No		25			01/08/2019	23/10/2020	18/11/2019	17/11/2020	17/11/2020	Please Select...	22/02/2021	Sponsor
173807	19/SC/0634	252084	Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial)	No		61			17/06/2020	05/11/2020	04/08/2020	14/12/2020	05/01/2021	Please Select...	05/01/2021	Neither

Q3 2020-21 Delivery												
	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50641	19/LO/1318	268820	A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and	Number Agreed	3	3	Date Agreed	01/03/2020	4	01/03/2020	4	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50642	18/EE/0222	233921	A randomised controlled trial of very early versus delayed angiography +/- intervention on outcomes in patients with non ST-elevation myocardial infarction	Number Agreed	25	25	Date Agreed	30/09/2020	0	19/03/2020	0	Withdrawn By Host

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50643	19/NW/0181	260431	A Randomized, Double-blind, Placebo-Controlled, Crossover, Dose Escalation Study of BLU-5937 in Subjects with Unexplained or Refractory Chronic Cough	Number Agreed	5	5	Date Agreed	31/01/2020	3	31/03/2020	3	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50644	19/NW/0001	253853	IDL-2965 ? A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis	Number Agreed	6	6	Date Agreed	01/02/2020	3	03/05/2020	3	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50645	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC inhibitor medication called ION-827359 in Healthy Volunteers and People With Cystic Fibrosis	Number Agreed	3	3	Date Agreed	31/03/2020	0	12/05/2020	0	Withdrawn By Sponsor
50646	19/NW/0506	269510	A Phase 3 study of the efficacy, safety and the body?s effects on a triple combination therapy of VX-445, tezacaftor and ivacaftor in children with cystic fibrosis aged 6 to 11	Number Agreed	1	1	Date Agreed	31/01/2020	3	31/01/2020	3	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50647	19/LO/0784	264744	A Pilot Study to exPlOre the exisTence and impact of FRAILTY in patients over the age of 70 undergoing cardiac interventions	Number Agreed	125	125	Date Agreed	03/01/2021	82	03/03/2020	82	Withdrawn By Sponsor

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50648	19/LO/1317	268821	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)	Number Agreed	3	3	Date Agreed	30/09/2020	3	20/04/2020	3	Recruitment Finished
50650	19/LO/0308	257755	VIVOTM non-invasive mapping of ventricular arrhythmia	Number Agreed	14	14	Date Agreed	17/09/2020	14	17/09/2020	14	Recruitment Finished

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50651	17/SW/0128	222284	Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation	Number Agreed	10	10	Date Agreed	31/10/2021	7	15/10/2020	7	Withdrawn By Sponsor
50652	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Number Agreed	5	5	Date Agreed	31/03/2020	1	16/10/2020	1	Withdrawn By Sponsor

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
50653	18/LO/2006	250980	A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, in the Absence of Antihypertensive Medications	Number Agreed	4	4	Date Agreed	01/04/2020	1	20/10/2020	1	Recruitment Finished

Q4 2020-21 Initiating															
	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173813	20/HRA/1696	282338	Ventilation Strategies in COVID-19; CPAP, High-flow, and standard care	No		0			14/04/2020	17/04/2020	03/04/2020	17/04/2020	17/04/2020	Please Select...	17/04/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173814	20/NW/0195	1003047	A Phase 3b randomised, placebo-controlled study of the efficacy and safety of a triple combination therapy of elexacaftor (VX-445), tezacaftor and ivacaftor in people with cystic fibrosis aged 6 to 11 with one F508del mutation and one minimal function mutation	No		104			28/02/2020	14/05/2020	14/05/2020	18/05/2020	26/08/2020	Please Select...	27/08/2020	Neither
173815	20/SC/0071	263083	High density substrate evaluation and guided ablation therapy for atrial fibrillation: Heat-AF	No		230			29/01/2020	01/04/2020	03/04/2020	17/11/2020	17/11/2020	Please Select...	17/11/2020	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173816	26/NW/0004	274499	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445/TEZ/IVA Combination Therapy in Subjects With Cystic Fibrosis Who Are 6 Years of Age and Older	Yes	########	24	39	63	19/02/2020	24/04/2020	24/04/2020	24/04/2020	18/05/2020	Please Select...	18/05/2020	Please Select...

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173817	20/LO/0749	1003158	A randomized, patients- and investigator blinded, placebo - controlled parallel group study to assess the mode-of-action of QBW251 in patients with Chronic Obstructive Lung disease (COPD).	No		217			31/12/2019	11/05/2020	26/06/2020	10/12/2020	14/12/2020	Please Select...	15/12/2020	Neither
173818	20/SC/0315	285603	EARSATS-19: In-ear measurement of blood oxygen saturation in COVID-19 follow up	No		48			20/08/2020	19/08/2020	19/08/2020	19/08/2020	06/10/2020	Please Select...	20/10/2020	Neither

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173819	20/NW/0089	275309	Grass Pollen Sublingual Tablet Immunotherapy plus Dupilumab for Induction of Tolerance in Adults with Moderate to Severe Seasonal Allergic Rhinitis	Yes	########	24	77	101	04/03/2019	25/09/2020	20/03/2020	19/10/2020	19/10/2020	Please Select...	19/10/2020	Sponsor
173820	20/NI/0137	285414	Fissure Closure with the AeriSeal? System for Converting Collateral Ventilation Status in Patients with Severe Emphysema; a Multicenter, Prospective Trial	No		141			29/09/2020	30/09/2020	27/01/2021	08/02/2021	18/02/2021	Please Select...	18/02/2021	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
173821	19/EM/0315	258745	Peri-Vascular adipose tissue inflammation Elevated using coronary CT angiography (P-VECT Study)	No		25			01/08/2019	23/10/2020	18/11/2019	17/11/2020	17/11/2020	Please Select...	22/02/2021	Sponsor
173822	19/SC/0634	252084	Treating severe paediatric asthma; a randomised controlled trial of mepolizumab and omalizumab (TREAT trial)	No		126			17/06/2020	05/11/2020	04/08/2020	14/12/2020	11/03/2021	Please Select...	05/01/2021	Sponsor

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
174246	20/NW/0371	1003390	"A Phase 3b Open-label Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects Ages 6 Years and Older Who Are Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)"	No		25			24/09/2020	04/01/2021	12/10/2020	07/01/2021	29/01/2021	Please Select...	15/02/2021	NHS Provider

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	First Participant Recruited?	Date of First Participant Recruited	Duration between Date Site Selected and Date Site Confirmed	Duration between Date Site Confirmed and First Participant Recruited	Duration between Date Site Selected and First Participant Recruited	Date Site Invited	Date Site Selected	HRA Approval Date	Date Site Confirmed By Sponsor	Date Site Confirmed	Non-Confirmation Status	Date Site Ready To Start	Reasons for delay correspond to:
174247	20/ES/0118	287333	A randomized, subject- and investigator-blinded, placebo controlled, parallel group study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of QBW251 in patients with bronchiectasis	No		51			10/11/2020	05/01/2021	11/01/2021	23/02/2021	25/02/2021	Please Select...	05/03/2021	NHS Provider

Q4 2020-21 Delivery

	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial

50654	**19/NW/0001**	**253853**	**IDL-2965 ? A Phase I, Randomized, Double-blind, Placebo-controlled, Single and Multiple Oral Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Subjects and Subjects with Idiopathic Pulmonary Fibrosis**	**Number Agreed**	**6**	**6**	**Date Agreed**	**01/02/2020**	**3**	**03/05/2020**	**3**	**Recruitment Finished**

50655	18/NI/0145	252483	A phase 1/2a study to assess various doses of an ENaC inhibitor medication called ION-827359 in Healthy Volunteers and People With Cystic Fibrosis	Number Agreed	3	3	Date Agreed	31/03/2020	0	12/05/2020	0	Withdrawn By Sponsor
50656	19/LO/1317	268821	A Phase 3, Open-label Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for the F508del Mutation and a Gating or Residual Function Mutation (F/G and F/RF Genotypes)	Number Agreed	3	3	Date Agreed	30/09/2020	3	20/04/2020	3	Recruitment Finished
50657	19/LO/0308	257755	VIVOTM non-invasive mapping of ventricular arrhythmia	Number Agreed	14	14	Date Agreed	17/09/2020	14	17/09/2020	14	Recruitment Finished
50658	17/SW/0128	222284	Assessment of the WATCHMAN Device in Patients Unsuitable for Oral Anticoagulation	Number Agreed	10	10	Date Agreed	31/10/2021	7	15/10/2020	7	Withdrawn By Sponsor

50659	19/EM/0101	260487	Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Efficacy and Safety Study with Inhaled RVT-1601 for the Treatment of Persistent Cough in Patients with Idiopathic Pulmonary Fibrosis (IPF): SCENIC Trial	Number Agreed	5	5	Date Agreed	31/03/2020	1	16/10/2020	1	Withdrawn By Sponsor
50660	18/LO/2006	250980	A Phase 2, Multicenter, Blinded, Sham Procedure-Controlled Trial of Renal Denervation by the Peregrine System Kit, in Subjects with Hypertension, in the Absence of Antihypertensive Medications	Number Agreed	4	4	Date Agreed	01/04/2020	1	20/10/2020	1	Recruitment Finished